- Patent Title: (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
-
Application No.: US17500367Application Date: 2021-10-13
-
Publication No.: US12076321B2Publication Date: 2024-09-03
- Inventor: Markus Ostermeier , Ulrike Werthmann
- Applicant: Centrexion Therapeutics Corporation
- Applicant Address: US MA Boston
- Assignee: Centrexion Therapeutics Corporation
- Current Assignee: Centrexion Therapeutics Corporation
- Current Assignee Address: US MA Boston
- Agency: Dechert LLP
- Priority: EP 175066 2015.07.02
- Main IPC: A61K31/506
- IPC: A61K31/506 ; A61K31/166 ; A61K31/351 ; A61K31/4545 ; A61P29/00 ; C07D405/14

Abstract:
The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same.
Public/Granted literature
Information query
IPC分类: